Premium
Treatment of multiple myeloma with carboquone‐prednisolone
Author(s) -
Akashi Makoto,
Sakamoto Shinobu,
Ohta Masatsugu,
Kitagawa Seiichi,
Yoshida Minoru,
Saito Masaki,
Takaku Fumimaro,
Miura Yasusada
Publication year - 1989
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1989.tb00110.x
Subject(s) - prednisolone , medicine , multiple myeloma , chemotherapy , clinical trial , oncology , combination chemotherapy , combination therapy , gastroenterology
18 previously untreated patients with multiple myeloma were entered in a clinical study of a combination chemotherapy, carboquone (CQ) and prednisolone (P) (CQ‐P). Response was observed in 44% of patients treated with CQ‐P judged by the criteria for response to chemotherapy. The median survival time was 33 months. Serious toxic reactions seldom occurred. The results suggest that the combination of CQ‐P has efficacy in the treatment of multiple myeloma and could have a role among primary chemotherapeutic regimens for the disease. Further clinical trials should be conducted to establish a new drug combination in which CQ is included.